STEPHENS ANNUAL INVESTMENT CONFERENCE | NASH2026 - CASTLE BIOSCIENCES INC
Explicit Guidance:
- FY2026 revenue midpoint increased by $20 million to a range of $385–395 million.
- FY2026 adjusted EBITDA expected to close at $12.7 million.
- FY2026 free cash flow (operating) projected at $19.7 million.
- FY2026 gross margin (adjusted) maintained near 77%, with a target range of 70–75% for 2027.
- 2027 adjusted EBITDA margin expected to remain positive, with potential mid-to-low single-digit volume growth for Melanoma (DecisionDX) and mid-single-digit volume growth for Tissue Cipher.
- Advanced Atopic Dermatitis (AD) test revenue contribution expected to scale measurably starting in 2027, aiming to become a primary revenue driver by 2029–2030.
Business-Segment Outlook:
- Tissue Cipher (GI): New clinician adoption remains a significant growth driver; 2026 census will show healthy growth in first-time ordering clinicians. Expansion of formal practice protocols is accelerating, with interventionist gastroenterologists leading adoption in some groups. 2027 is viewed as "cleaner" regarding revenue accruals compared to the overlaps in 2026.
- Melanoma (DecisionDX): Current penetration estimated at 30–40% (testing 1 in 3 to 4 in 10 invasive cases); target penetration is 60% absent major upstream interventions. Potential for penetration to reach 80%+ if successful upstream melanoma vaccine/immunotherapy interventions emerge.
- Advanced Atopic Dermatitis (AD): Aspirationally serves a 20-fold larger TAM than Tissue Cipher (8–11 million patients). 2027 focus is on measured volume generation and meeting reimbursement milestones (CMS crosswalk) to enable commercial scaling.
- Squamous Cell Carcinoma (SEC): Viewed as a "nice-to-have" catalyst for 2028; not essential for near-term 2027 growth but critical for long-term potential.
- Pipeline/Innovation: Development ongoing for a tether sponge device for Barrett's esophagus; potential launch dependent on clinical data and payment pathway validation. Exploration of external collaboration on electrical impedance spectroscopy (EIS) technology ("highlighter pen") with potential to become a major product ahead of AD if results materialize.
Market and Competitive Outlook:
- Payer Landscape: Commercial payer wins and improved appeal success rates are driving ASP stability. Medicare Advantage plans showing improved payment percentages (approaching 100% for compliant claims) due to better engagement.
- Workflow Integration: GI adoption faces structural "breakage" between surgical/clinic staff; focus is on EMR automation and formalized protocols to close gaps. Melanoma market remains promotionally responsive.
- Lucid Diagnostics: Non-endoscopic collection devices (sponges) expected to increase the diagnostic funnel starting late 2027–2028, with acceleration expected by 2029–2030.
- Pricing Dynamics: Assuming a mature marketplace, the tether sponge device could price at ~50% of current Tissue Cipher ASPs due to demographic shifts (50% patients <65 years old).
Macro / Industry Outlook:
- Regulatory (CMS): Anticipation of final Medicare rates for Dec 2026 release in early-mid December 2027. Management expects a "crosswalk" (not a gap fill) for the Advanced AD test, targeting a rate in the ~$1,300 range based on submitted NGS/RNA comparator data.
- Guideline Updates: Expectation for DecisionDX-Melanoma to be positively incorporated into NCCN guidelines in the January 2027 panel update following submission of new data (July 2025+).
- Coverage Trends: SEC (Squamous Cell Carcinoma) coverage via Novitas is a key near-term variable; potential for draft LCD or CAC meeting in the next quarter or two, though a 2028 launch remains a conservative base case.
- Market Structure: No expectation of incremental ASP upside from Medicare claims (highly forecastable); upside driven by commercial payer penetration and Medicare Advantage resolution.
Strategic Initiatives:
- Sales Force Expansion: GI sales team (~100 reps) reaching full productivity by Q4 2027 following 6-month training cycles; measured territory expansion expected in 2027.
- Capital Allocation: FY2026 ending with ~$278 million in cash and marketable securities; balance sheet strength supports growth without external financing.
- R&D Investment: Increased R&D spending anticipated in 2027 to support Tissue Cipher GI expansion, pipeline milestones (tether sponge), and external EIS collaboration; costs weighed against maintaining profitability.
- Workflow Automation: Investment in EMR integration solutions to automate test ordering flags for Barrett's disease to mitigate staff turnover and workflow breakage.
Risks and Headwinds to Outlook:
- Reimbursement Uncertainty: Risk of CMS finalizing a "gap fill" rate for the AD test rather than a crosswalk, potentially delaying commercial expansion.
- Regulatory Delays: Potential delays in SEC (Novitas) coverage finalization; no guaranteed timeline from draft to finalization for LCDs.
- Volume vs. Reimbursement Mismatch: Pressure on gross margins (potential drop to low 70s) if AD volume scales rapidly before reimbursement clarity is established.
- Adoption Friction: Structural workflow gaps in GI practices (surgical vs. clinical staff separation) could slow protocol adoption rates despite clinical utility.
- Medical Innovation: If upstream melanoma interventions (vaccines/immunotherapy) fail to advance, the penetration ceiling for DecisionDX may remain capped at 60%.
Management Tone on the Future:
- Confidence: Highly confident in the 2026 financial results and balance sheet strength ("strong position").
- Cautious Optimism: Deliberately conservative on timing for SEC recovery (pushed to 2028) and AD scaling (measured approach in 2027) to manage investor expectations.
- Strategic Pivot: Shift from "building a profitable company" to "scaling a profitable company," acknowledging that the business is now self-sustaining but growth requires navigating reimbursement and workflow complexities.
- Resilience: Emphasis on a "plan B" where the company meets goals even without SEC recovery, driven by the Advanced AD test and Tissue Cipher organic growth.
Miscellaneous:
- Cash Position: ~$278 million in cash and marketable securities at end of 2026.
- Segment Synergies: Potential for the EIS technology to outperform the Advanced AD test in market potential if early study results are productive.
- Historical Context: FY2025 SEC revenue wind-down attributed to the April 2025 Medicare decision; 2026 growth is now driven by commercial wins and operational efficiency.
- Company
- CASTLE BIOSCIENCES INC
- Keywords
- CASTLE BIOSCIENCES INC